Compare ANIP & WT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANIP | WT |
|---|---|---|
| Founded | 2001 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.4B |
| IPO Year | 1999 | 2011 |
| Metric | ANIP | WT |
|---|---|---|
| Price | $76.28 | $15.66 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 3 |
| Target Price | ★ $107.33 | $17.08 |
| AVG Volume (30 Days) | 298.2K | ★ 2.2M |
| Earning Date | 05-11-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 0.73% |
| EPS Growth | ★ 419.23 | 127.27 |
| EPS | ★ 3.32 | 0.75 |
| Revenue | $206,547,000.00 | ★ $493,753,000.00 |
| Revenue This Year | $19.88 | $33.08 |
| Revenue Next Year | $15.77 | $7.39 |
| P/E Ratio | $22.90 | ★ $21.80 |
| Revenue Growth | 2.47 | ★ 15.43 |
| 52 Week Low | $56.71 | $7.47 |
| 52 Week High | $99.50 | $17.68 |
| Indicator | ANIP | WT |
|---|---|---|
| Relative Strength Index (RSI) | 46.83 | 42.23 |
| Support Level | $75.20 | $15.38 |
| Resistance Level | $84.47 | $17.09 |
| Average True Range (ATR) | 2.44 | 0.59 |
| MACD | 0.15 | -0.22 |
| Stochastic Oscillator | 61.39 | 8.86 |
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
WisdomTree Inc is a financial innovator, offering a diverse suite of Exchange-traded products (ETPs), models and solutions, private market investments and digital asset-related products. It also offers digital products and services related to tokenized real world assets and stablecoins, including tokenized mutual funds (Digital Funds), as well as its institutional platform, WisdomTree Connect, and blockchain-native digital wallet, WisdomTree Prime. The company's products are distributed across various asset management industry channels, including banks, brokerage firms, registered investment advisers, institutional investors, private wealth managers and online brokers. The majority of the company's revenue is generated from advisory fees earned from ETPs.